icon-folder.gif   Conference Reports for NATAP  
 
  HIV Drug Therapy Glasgow
November 2-6, 2014
Glasgow, UK
Back grey_arrow_rt.gif
 
 
 
Phase IIIb, open-label, single-arm trial of darunavir/cobicistat: Week 48 subgroup analysis of HIV-1-infected, treatment-na´ve adults - PK/virology/safety/tolerability
 
 
  Reported by Jules Levin
Presented at the 12th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2-6 November, 2014
 
Karen Tashima,1 Gordon Crofoot,2 Frank L Tomaka,3 Thomas N Kakuda,3 Anne Brochot,4 Simon Vanveggel,5 Magda Opsomer,5 William Garner,6 Nicolas Margot,6 Joseph M Custodio,6 Marshall W Fordyce,6 Javier Szwarcberg6 1The Miriam Hospital, Providence, RI, USA; 2Gordon Crofoot Research, Houston, TX, USA; 3Janssen Research & Development LLC, Titusville, NJ, USA; 4Janssen Research & Development, Beerse, Belgium; 5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Gilead Sciences, Foster City, CA, USA

Glasgow1.gif

Glasgow2.gif

Glasgow3.gif

Glasgow4.gif

Glasgow5.gif

Glasgow6.gif